Please login to the form below

Immunotherapy in oncology

Consultant David Cooney explores the medical insights, unmet needs, and future of the vastly growing area of immunotherapy as the fourth pillar in oncology.
We’ve been killing cancer cells for years. We’ve poisoned them, starved them, targeted them, lysed them, and irradiated them - even cut off their blood supply. This has led to major progress in disease control and prolonging the survival of cancer patients, but there are still major areas of unmet need. We are certainly some distance away from the Obama administration’s moon-shot of curing cancer… or are we?Immunotherapy has progressed at a phenomenal rate over the last 5 years, and it is now seen as the fourth pillar of care in oncology. To date, Blue Latitude Health have worked with 4 of the 9 immunotherapies currently approved by the FDA, and this article will provide an overview of the area; sharing some of the scientific, medical and commercial insights we have picked up as well as the topics we anticipate will shape the future of this exciting and innovative pillar of cancer care.

What is Immunotherapy?

Immunotherapy, is a type of cancer treatment designed to boost the body’s natural defences to fight the cancer. It uses materials either made by the body or in a laboratory to improve, target, or restore immune system function.

To understand the value of immunotherapy, it is important to consider the dynamic relationship between a tumour and the immune system. This can include anti-tumour immunity and tumour-promoting inflammation; the process is known as immunoediting.

Three states of interaction exist in immunoediting;
  1. Elimination, in which the immune response eradicates cancer cells
  2. Equilibrium, in which the immune response controls tumour growth
  3. Escape, in which the tumour outgrows the immune response.
These three states align with the clinical observations of response, stable disease and progression of disease. However, what is critical about this concept is an understanding that there is a survival benefit when a patient is in both a state of elimination and equilibrium.

This is very different to how we currently assess chemotherapies – by their response rates – where stable disease would be perceived as a poor response. With immunotherapies, even patients with stable disease have experienced significant survival benefit while responders have far exceeded the typical expectancy. 

This was the case with the development of ipilimumab (Yervoy) where response-based endpoints (overall response rate [ORR] and progression free survival [PFS]) were the primary endpoints of the phase II trials. This yielded results of 5-15% ORR, which were relatively low at inspection. However, the group recognised that delayed responses and prolonged stable disease were having a significant survival benefit, underscoring the clinical benefit of the therapy. This led to a changing of the primary clinical endpoint for the phase III trials to survival, which proved pivotal in demonstrating the clinical value of ipilimumab and leading to its approval by the FDA in March 2011.

This was a crucial learning in how we interpret immunotherapeutic data, and led to the development of the immune-related response criteria (irRC). This criteria will be critical to the development of immunotherapies as well as the correct use of these therapies in the clinic. One of the phenomenon we have seen with products we have worked with is tumour flare, where tumours or lesions increase before they can shrink. This has also been called pseudo-progression, and poses a risk of patients being taken off treatment before the benefit of the therapy has taken effect.

Time is a critical factor in immunotherapy due to the nature of the immune system, and understanding the different systems for immunity help shine a light on why responses take time.


Download the full article from Blue Latitude Health

5th August 2016

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget.
Blue Latitude Health
Innovative approaches in the treatment of multiple sclerosis
Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon.
Blue Latitude Health
Q&A with Dr Timothy Vollmer, leading MS Neurologist
Blue Latitude Health sits down with key opinion leader and specialist neurologist Dr Timothy Vollmer to better understand the paradigm shift in MS treatment. He explains the challenges neurologists face when making treatment decisions, and why patients need to be treated with more efficacious drugs earlier on.
Blue Latitude Health
Living my best life with multiple sclerosis
Multi-award-winning advocate and patient engagement champion Trishna Bharadia gives a valuable insight into life with multiple sclerosis. She explains how treatment has changed, how our healthcare systems and pharma can unite to improve quality of life for MS patients today, and why her diagnosis isn’t stopping her achieving her goals.
Blue Latitude Health
Creative review: ESMO 2018
BLH reviews the creative concepts exhibited at the European Society for Medical Oncology (ESMO) 2018 Congress, crowning our best booth winners and giving key insights on how to develop an inspiring design for your booth.
Blue Latitude Health
A unique tool for turning data into brand strategy
Head of Insight Martine Leroy, uses her 25+ years’ experience to develop an exclusive perceptual framework for research design and analysis, which generates a deeper understanding of customer needs and the changing market dynamics
Blue Latitude Health